Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Piccari On Behalf Of The Rehar Registry (Barcelona, Spain), P. Vitulo (Palermo, Italy), S. Wort (London, United Kingdom), F. Meloni (Pavia, Italy), A. Bertani (Palermo, Italy), I. Blanco (Barcelona, Spain), L. Price (London, United Kingdom), E. Salvaterra (Pavia, Italy), M. Beretta (Palermo, Italy), V. Pérez Rodríguez (Madrid, Spain), C. Mc Cabe (London, United Kingdom), E. Cattaneo (Pavia, Italy), A. Callari (Palermo, Italy), M. López Meseguer (Barcelona, Spain), L. Scelsi (Pavia, Italy), D. Rodríguez (Barcelona, Spain), J. Barberà (Barcelona, Spain), L. Martino (Palermo, Italy), F. Tuzzolino (Palermo, Italy). Impact of borderline (BL) pulmonary hypertension (PH) in chronic lung diseases (CLD).. 293

Member's Comments

No comment yet.

Related content which might interest you: Comparison of pulmonary hypertension (PH) associated to chronic lung disease to other PH groups Source: International Congress 2016 – Pulmonary hypertension in lung disease Year: 2016 Pulmonary rehabilitation (PR) outcomes in chronic obstructive pulmonary disease (COPD) compared with interstitial lung disease (ILD) Source: Annual Congress 2011 - Pulmonary rehabilitation: looking at alternative approaches and alternative populations beyond COPD Year: 2011 Pulmonary arterial hypertension (PAH) among end state renal disease (ESRD) patients under chronic hemodyalisis (HD) Source: Eur Respir J 2007; 30: Suppl. 51, 345s Year: 2007 Pulmonary hypertension (PH) and features of pulmonary circulation in patient with lung sarcoidosis (LS) Source: Eur Respir J 2006; 28: Suppl. 50, 354s Year: 2006 Relationship between pulmonary hypertension (PH) and lung function in severe COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 252s Year: 2001 Differential therapy of acute respiratory failure (ARF) in chronic obstructive pulmonary disease (COPD) patients with predominance of emphysema (PE) and predominance of bronchitis (PB) Source: Eur Respir J 2006; 28: Suppl. 50, 395s Year: 2006 Inflammatory biomarkers in patients with COPD and pulmonary hypertension (PH). Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019 The indices of body composition (IBC) in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2011 - COPD diagnosis Year: 2011 The role of secondary pulmonary hypertension (SPH) in the limited exercise tolerance of patients with interstitial lung disease (ILD) Source: Eur Respir J 2005; 26: Suppl. 49, 560s Year: 2005 Hedgehog-interacting protein (HHIP) polymorphisms and chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2011 - Genetic and environmental risk factors for respiratory diseases Year: 2011 Pulmonary arterial hypertension (PAH) in patients with lung sarcoidosis (LS) Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008 Hypoxic challenge testing (HCT) in COPD and pulmonary hypertension (PH) Source: Eur Respir J 2004; 24: Suppl. 48, 326s Year: 2004 Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 Increased prevalence of obstructive airways disease (OAD) in patients with ischemic heart disease (IHD) and hypertension (HT) Source: Eur Respir J 2007; 30: Suppl. 51, 122s Year: 2007 Pulmonary hypertension (PH) in chronic hemodialysis (CHD) patients is associated with inflammatory markers and volume overload Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 The composite physiological index strongly predicts mortality in interstitial lung disease (ILD) associated pulmonary hypertension (PH-ILD) Source: International Congress 2017 – Imaging and lung disease PH Year: 2017 Benefits of pulmonary rehabilitation (PR) in patients with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) having the same dyspnoea severity Source: International Congress 2018 – What’s hot in rehabilitation in COPD and interstitial lung disease (ILD)? Year: 2018 Predictive factors for the incidence of lung cancer (LC) complicated in patients with chronic obstructive pulmonary disease (COPD) Source: International Congress 2019 – Advances in clinical management of COPD Year: 2019 The influence of diabetes type 2 (D2) on pulmonary hypertension (PH) in COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 60s Year: 2005 Influence of bronchodilators on pulmonary hypertension (PH) in patients with moderate and severe chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2005; 26: Suppl. 49, 310s Year: 2005